Drug intelligence / Profile preview

bifidobacterium longum FGDLZ8M1

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium longum FGDLZ8M1 is a specific probiotic strain of Bifidobacterium longum, a Gram-positive, rod-shaped bacterium commonly found in the human gastrointestinal tract. This strain has demonstrated significant anti-inflammatory and immune-modulatory effects in preclinical models of ulcerative colitis. In particular, B. longum FGDLZ8M1 was shown to alleviate colitis symptoms by reducing pro-inflammatory cytokine expression, restoring colon length, and maintaining mucosal integrity. Its mechanism involves inhibition of NF-κB signaling pathways and enhanced tolerance to gastrointestinal transit conditions such as bile salts and acids[1]. Like other B. longum strains, it contributes to gut health by fermenting carbohydrates into short-chain fatty acids (SCFAs), supporting intestinal barrier function, and modulating the gut microbiome[2][4].

Other names: 长双歧杆菌FGDLZ8M1

Targets

NF-κB

Beyond the preview

Go deeper on bifidobacterium longum FGDLZ8M1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium longum FGDLZ8M1.

Explore the full profile